MedPath

Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy

Phase 3
Conditions
Uterine Myoma
Uterine Adenomyosis
Registration Number
NCT01483417
Lead Sponsor
Samsung Medical Center
Brief Summary

Multi-center prospective randomized trial of single port laparoscopic surgery (SILS) versus conventional 3-4 ports laparoscopic hysterectomy. Hypothesis is that conversion rate of SILS is not inferior to that of conventional approach.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
240
Inclusion Criteria
  • Symptomatic (dysmenorrhea, palpable mass, pelvic pain or discomfort urinary symptom, increasing size, menorrhagia) myomas or adenomyomas
  • Uterine size < gestational age of 14 weeks
  • Informed consent
Exclusion Criteria
  • Medical diseases such as heart failure, renal insufficiency, liver cirrhosis, pancreatitis, uncontrolled DM
  • Huge uterine size > gestational age of 14 weeks

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Conversion rate1 week

Conversion means that events required additional port(s) or open laparotomy

Secondary Outcome Measures
NameTimeMethod
Patient and Observer Scar Assessment Scale (POSAS)12 weeks
Postoperative painpostop. 1 day, 1 week

Measured by numeric rating score (NRS)

Trial Locations

Locations (8)

Keimyung University Dongsan Hospital

🇰🇷

Deagu, Korea, Republic of

Catholic Incheon Hospital

🇰🇷

Incheon, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Kangnam Cha Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul Catholic Medical Center

🇰🇷

Seoul, Korea, Republic of

Yonsei University Medical Center

🇰🇷

Seoul, Korea, Republic of

Seoul University Bundang Hospital

🇰🇷

Seungnam, Korea, Republic of

Keimyung University Dongsan Hospital
🇰🇷Deagu, Korea, Republic of
Chi-Heum Cho, MD,PhD
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.